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A B S T R A C T
Molecular network of the osteogenic BMPs and extracellular inhibitors maintains homeostasis of the skeletal tissues.
It is important to determine relationship between BMP-2, -4 and -7 and their inhibitors: gremlin, follistatin, chordin and
noggin, during normal osteogenesis. To determine their expression pattern we conducted investigation by inducing ecto-
pic bone formation in rats. The results shown that levels of the BMP-2 and BMP-4 expression in chondrocytes are similar
to noggin and follistatin. The latter BMPs and inhibitors have increased levels of the expression at day 14th of the osteo-
genesis, which suggests their important roles in early phases of the chondrogenesis. Gremlin and chordin have shown
increased levels of expression in late phase of chondrogenesis, which suggests their important role in regulation of the
osteogenesis initiation. In this study, BMPs and inhibitors have the highest levels of the expression at 21st day in the
osteocytes, which suggests their strong interactions in osteogenesis.
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Introduction
Physiological mechanisms of the osteogenesis such as
bone growth, development and fracture healing or patho-
logical mechanisms such as development of the osteo-
phyte in osteoarthritis are known in many details. How-
ever, discovery of extracellular inhibitors, has driven much
attention to understanding their roles and interactions
with BMP-2, BMP-4, and BMP-7, especially since BMP-2
and BMP-7 have been applied in therapy of some clinical
conditions. BMPs activities are modulated during osteo-
genesis by several unrelated secreted proteins collecti-
vely known as BMP antagonists, which bind to the BMPs
and prevent their binding and signaling through their
specific receptors. Those are primary: follistatin, grem-
lin, chordin and noggin. Studies performed on human
joint tissues, that involve BMP antagonists have been re-
ported by several researchers1–4.
Tardif et al. were the first authors that have indicated
to important role of the folistatin i gremlin in patho-
physiology of the osteoarthritis1. In the cell culture of the
osteoarthritic (OA) chondrocytes afore mentioned authors
have noticed strong stimulation of the gremlin gene ex-
pression, but downregulation of the follistatin gene ex-
pression after BMP-2 and BMP-4 were added. In the same
study, spatial distribution of the gremlin, BMP-2 and
BMP-4 was similar in middle and upper layers of the OA
cartilage, which is similar to result of Nakase. Immunolo-
calization of the BMP-2 was found in chondrocytes of the
OA cartilage as well as in the ostheophyte5. This data
supports the opinion that the follistatin and gremlin are
differentially regulated in OA chondrocytes. When the
expression of the follistatin, gremlin, chordin and noggin
was compared between OA chondrocytes and controls,
then significantly higher expression of the folistatin and
gremlin was found in OA, chordin expression did not sig-
nificantly differed between OA and controls, while noggin
expression was not detected in OA nor in the controls.
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During early phase of the intramembranous ossifica-
tion, Kwong et al. have determined that endogenous pro-
duction of chordin and BMP-2 have increased during dif-
ferentiation of the mesenchymal cells to bone cells6. Also,
the suppression of chordin improves early osteogenesis,
which was demonstrated by increased BMP-2
bioavailability. Such result confirms earlier findings of
Petryk et al. of limited in vitro osteogenesis after exoge-
nous application of the chordin7. Investigation on the hu-
man long bone fracture repair has detected interaction of
the BMP-2 and its inhibitors chordin and noggin. BMP-2
is strongly expressed in hypertrophic chondrocytes,
while noggin and chordin were expressed equally in hy-
pertrophic and non-hypertrophiy chondrocytes of the ar-
eas of endochondral ossification4.
Recent researches of Tardif et al. indicate to upre-
gulation of the chordin expression in OA chondrocytes,
compared to controls, and increased expression of the
gremlin and follistatin, as well as BMP-2 and BMP-4 in
experimental model of the OA1-3.
Afore mentioned studies indicate to complex relation-
ships between BMPs and BMP antagonists during pro-
cess of the osteogenesis. In this study of the experimental
model of the ectopic ossification, temporospatial expres-
sion of the osteogenic BMPs and their inhibitors, trough
process of physiological osteogenesis is evaluated.
Previous research lack data of the temporal and histo-
logical distribution of the expression of the BMP’s antag-
onists during the osteogenesis. Physiological balance of
the molecular network of the osteogenic BMPs and ex-
tracellular inhibitors maintains homeostasis of the skele-
tal and joint tissues. Therefore, it is important to deter-
mine relationship between BMP-2, BMP-4 and BMP-7 and
their specific inhibitors: gremlin, follistatin, chordin and
noggin, during normal osteogenesis. Such result is a
starting point in better understanding of the relation-
ships between BMPs and their specific inhibitors in de-
generative joint diseases.
Materials and Methods
The study was performed on 130 female Wistar rats, 4
weeks of age, weighing 250 g. Experimental animals
were kept under standard conditions and fed by standard
food for laboratory mice and rats ad libitum. Animals are
allowed free movement in plastic cages measuring
50x25x25 cm and were exposed to normal cycle of dark-
ness and light (12h:12h). Study groups comprised 12 ani-
mals. Control group underwent sham operation.
This study was approved by the Institutional Ethics
Committee.
Experimental procedures
Preparation of demineralized bone matrix
Demineralized bone matrix (DBM) powder was pre-
pared out of the long bones of the posterior limb of 30
rats. Bones were rinsed with saline and the bone marrow
along with the periosteum was removed. Bones were
dried in a thermostat at 37°C and grinded into powder.
Size of the bone particles within powder amounted
70–150 mm. Bone powder was demineralized by use of
the 0.5 M hidrochloride acid, washed with water and in-
cubated in 200 mM of the Tris buffer (pH 8.0). Deminer-
alized bone powder was washed with deionised water, al-
cohol and ether and dried at room temperature8-11.
Implant preparation
For implant preparation, 35 mg of DBM, along with
50 ml of the chondroitin sulfate solution and 50 ml of of
the collagen type I, was put into siliconized tube and cen-
trifuged for 15 minutes at 12000 rpm. Drying was done
at 37°C for 24 h in the thermostat.
Surgical procedure
Each implant was embedded subcutaneously in the
left and right pectoral region. Animals were anesthetized
by intraperitoneal injection of 3.6% chloral-hydrate (Sigma-
-Alorich, Germany). Procedures were performed under
conditions of asepsis and antisepsis. Animals were sacri-
ficed after excessive dose of anesthetic, injected inside




At given time periods, implants were collected from
each animal. Implants were decalcified in 0.5 M EDTA
for a week. Decalcified implants were fixed in 4% para-
formaldehyde for 24 hours and cut at microtome on 5 mm
thick tissue slides (Leica RM 2155 Rotary-microtome,
Leica Instruments GmbH, Germany). Preparations were
dehydrated in alcohols with different concentrations
(50%, 70% and 96%). For histologycal analysis, hemalaun-
-eosin, toluidine blue and Goldner stainings were done.
Imunohistochemistry
Time and spatial distribution of the BMP-2, BMP-4
and BMP-7 and their antagonists: gremlin, nogin, chor-
din and follistatin expression were determined by use of
the immunohistochemistry Briefly, imunohistochemical
procedure was done according to the protocol described
in the literature12,13. For immunohistochemical staining
the following primary antibodies were used: goat poly-
clonal anti-human antibody gremlin-1 (N-20), rabbit
polyclonal anti-human noggin antibody (L-18Z), mouse
polyclonal anti-human follistatin antibody (H-114), rab-
bit polyclonal anti-human antibody chordin (K-25),
mouse polyclonal anti-human antibody against BMP-2
(mAHuBMP-2), goat polyclonal antibody anti-human
BMP-4 (N-16) and goat polyclonal antibody anti-human
BMP-7 (T-12). All primary antibodies were purchased
from Santa Cruz Biotechnology Inc., USA. Secondary an-
tibodies were purchased from the manufacturer Dako
(Denmark).
Morphometric analysis
Immunopositive cells were counted by use of the mi-
croscope at 40x power magnification (Olympus BX 50).
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Microphotographs of the specimens were taken by Olym-
pus OM-4 Ti camera (Olympus, Japan). Immunopositive
cells were counted in the tissue area of the implant that
contains at least 100 cells of interest. Results were ex-
pressed as percentage of the immunopositive cells. Each
slide was subjected to a double-blind evaluation.
Statistical analysis
Data are expressed as the X±S.E.M. Repeated Mea-
sures ANOVA and Fisher Post-hoc test were used to de-
termine specific differences between groups. p values less
than 0.005 were considered significant.
Results
Histomorphological changes in implants
at the critical temporal points
In the implants at the 5th day of the experimental pro-
tocol, a firm connective fibrous membrane on the surface
of the implants was detected. It was consisted of elon-
gated fusiform fibroblasts, with their long axis parallel to
the surface of the implants. Between single fibroblasts
blood vessels which morphologically correspond to capil-
laries and arterioles were found. Fibroblasts and blood
vessels were also found at the periphery of the implant.
Surface of the demineralized bone particles within the
implant is subjected to multinuclear cells degradation,
observed as lacunae and fissures. Also, fibroblast - like
cells infiltrated the central part, without blood vessels.
In the implants at the 7th day of the experimental pro-
tocol, similar morphological features to those of the 5th
day were characterized by: thick fibrous membrane at
the surface, high cellular infiltration between bone parti-
cles, numerous blood vessels and increased resorption.
At the 14th day the first signs of the induced chondro-
genesis are seen. Chondrocytic nests, consisted of hyper-
trophic chondrocytes, surrounded with the small amount
of the metachromatic extracellular matrix are situated in
between the DBM particles. (Figure 1. a, b). Also, cellular
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Fig. 1. A. Histomorphology of the central area of the implant. Chondrocytes (arrows) surrounds the bone particles of the implant (P).
The cartilage matrix is minimal. In the particles empty osteocytes lacunae (arrowheads) are visible. Goldner staining. B. Area of the
cartilage formation in the implant. Chondrocytes (arrows) are between DBM implant particles (P). Toluidine blue staining. C. Histo-
morphology of the area of the bone formation within the DBM implant. Spiculas of the new formed trabecular bone (B), marrow spaces
(MS) and osteocytes (arrows) are visible. Edges of the particles of the DBM are eroded. Goldner staining. D. Histomorphology of the area
of the intramembranous bone formation in the DBM implant. Spiculas of the new formed trabecular bone (B) and marrow spaces (MS)
are visible. Bone cellular elements are in the different stages of differentiation; there are visible osteocytes in the lacunae (arrows) and
the osteoblasts (arrowheads) on the surface of the new formed bone and on the surface of the marrow spaces. Connective tissue (CT) con-
tains a osteoprogenitor cells. Edges of the particles of the DBM are eroded. Goldner staining. Bar=200 mm.
infiltration, bone particle degradation and blood vessels
penetration are seen.
At the day 21, some cartilage nests are degradated.
Newly formed bone trabeculae, built of immature woven
bone tissue are seen on the surface of the implant. Be-
tween bone particles, three-dimensional network of the
bridging bone trabeculae is seen (Figure 1. c, d).
At the 30th day of the experimental procedure for com-
plete degradation of the implants is present.
Imunohistochemistry
The expresion of the most potent osteoinductive BMPs
(BMP-2, BMP-4, BMP-7) is analyzed.
Immunolocalization of the BMP-2 and BMP-4
BMP-2 and BMP-4 were expressed in very similar pat-
tern. At the 5th day, BMP-2 and BMP-4 were mainly local-
ized in the fibroblasts (Figure 2. a, f). At the 7th day,
immunolocalisation of the BMP-4 in fibroblasts was
stronger than those of the BMP-2 (Figure 2. b, g). At days
14th and 21st, except in fibroblasts, BMP-2 and to less ex-
tent, BMP-4, were expressed in hypertrophic chondro-
cites (Figure 2. c, h) and in osteoblasts (Figure 2. d, i). At
the day 30th, the expression of the BMP-2 and BMP-4 was
negative (Figure 2. e, j).
Immunolocalization of the BMP-7 in the implant
At the day 5th BMP-7 was expressed in fibroblasts and
also in the blood vessels layer (Figure 2. k). Contrary to
BMP-2 and BMP-4, BMP -7 was not expressed in hyper-
trophic chondrocytes at the day 14th (Figure 2. m). At the
day 21st, strong expression of the BMP-7 was observed in
osteoblasts (Figure 2. n). Alike to other BMPs at the 30th
day, BMP-7 expression was negative (Figure 2. o).
Imunolocalization of the BMPs inhibitors
in the implant
The expression of chordin, gremlin, noggin and
follistatin was analyzed. Compared to other inhibitors,
follistatin was the most intensity expressed inhibitor
(Figure 3. a - e). The expression pattern of all inhibitors
was the same (Figure 3. f - t). At the days 5th and 7th, in-
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Fig. 2. Immunolocalization of the BMP-2, BMP-4 and BMP-7 during ectopic osteogenesis in the DBM implants at 5th, 7th, 14th, 21st and
30th days of experiment. BMP-2 was expressed very weakly at day 5th and 7th (a, b) and very strongly at day 14th (c) in the infiltrated
fibroblastic cells. Also, BMP-2 was expressed in the hypertrophic chondrocytes at day 14th (c - arrows) and in osteocytes at day 21st (d -
arrows). At the end of the experiment at day 30th (e). BMP-2 expression is negative. The highest BMP-4 expression was detected at day 7th
in the infiltrated fibroblastic cells (g - arrows). Few chondrocytes were positive for BMP-4 at day 14th (h - arrows) and 21st during active
ostegenesis. BMP-4 was detected in the most of osteoblastic cells and cells of the marrow spaces (i - osteoblasts are pointed by arrows;
marrow spaces are pointed by asterixs). At day 30th BMP-4 expression is negative (j). BMP-7 was firstly expressed at 5th day (k), and
thereafter BMP-7 expression was negative until day 21 when it is positive mainly in osteoblastic cells and osteocytes (n). As for BMP-2
and BMP-4, BMP-7 was negative at day 30th (o). Bar=200 mm.
hibitors were immunolocalized in the membrane around
the implants, and also in fibroblasts (Figure 3. a, b). At
the day 14th, inhibitors were expressed in the hype-
trophic chondrocytes (Figure 3. c), and at the day 21st in
osteoblasts (Figure 3. d). At day 30th, inhibitors were ex-
pressed in the marrow spaces (Figure 3. j, e, o and t).
Temporal expression of the BMPs and inhibitors
The highest expression of all BMPs and inhibitors
was observed in osteocytes (Figure 4). At days 14th and
21st significantly lower expression of BMP-7 was found in
chondrocytes, compared to osteocytes of the 21st day
(p<0.005). BMP-2 and BMP-4 expression level were sig-
nificantly higher in chondrocytes at day 14, which means
in earlier phase of chondrogenessis (p<0.005). However,
BMP-2 and BMP-4 expression levels were significantly
higher in osteocytes of the 21st day, compared to chon-
drocytes (p<0.005). BMP inhibitors expression level in
chondrocytes showed different pattern in relation to
BMPs. Gremlin and chordin were expressed strongly in
chondrocytes of the 21st day, compared to 14th day. Con-
trary, follistatin and noggin showed higher expression
level in chondrocytes at day 14, compared to day 21st.
Temporal expression of the BMPs and inhibitors
in the chondrocytes
Statistical analyses showed significantly less number
of the BMP-7 positive chondrocytes at days 14 and 21,
compared to BMP-2 and BMP-4 (p<0.005) (Figure 4). At
days 14th and 21st, BMP-2 expression was significantly
higher, compared to BMP-4. (p<0.005). Analysis of ex-
pression of the BMP inhibitors revealed the lowest ex-
pression of the gremlin, at day 14th, compared to noggin
and follistatin (p<0.005). At day 21st, the least number of
the follistatin positive chondrocytes significantly differed
to gremlin, chordin and noggin (p<0.005).
The expression of the BMPs and inhibitors in the
fibrocytes
The highest number of the BMP-7 positive fibrocytes
was detected on 21st day, which is significantly different
to 5th day (p<0.005) (Figure 5). The highest expression of
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Fig. 3. Immunolocalization of the BMPs inhibitors during ectopic osteogenesis in the DBM implants at 5, 7, 14, 21 and 30 days of the
experiment. All studied BMP’s inhibitors showed similar paterns of distribution, but their expression levels were differed. Among them,
follistatin showed the strogest expression and was positive during the whole experiment (a - e). Follistatin was positive in fibroblast like
cells (a, b - arows), few hypertrophic chondrocytes (c - arows) and marowspaces (d - asterix), osteoblast and osteocytes of the newly
sintesized bone (d - arows). At day 30 follisattin expression still persisted in the marow spaces (e). Folistatin is expressed during the
whole period of experiment in membrane surounding the implats, fibrocytes from the membrane (at day 5th and 7th) (a, b), hypertrophic
chondrocyte (at day 14th) (c) and osteoblast of the newly sintetized woven bone (at day 21st) (d). At day 30th follistatin expression was
localised mainly in the cells of the remaining marrow spaces (e). Bar=200 mm.
the BMP-2 and BMP-4 was detected on days 21 and 30,
which significantly differed to days 5th and 7th (p<0.005),
respectively.
Compared to other inhibitors, follistatin had the high-
est expression in fibrocytes. More gremlin positive
fibrocytes were found at days 5th, 7th and 14th, which is
significantly different to 21st and 30th day (p<0.005), re-
spectively.
Disscussion and Conclusion
In our study BMP-7 expression is similar to BMP-2 and
BMP-4 in osteocytes, but significantly different in chon-
drocytes. Namely, BMP-2 and BMP-4 were strongly ex-
pressed in chondrocytes than BMP-7. This is in consistence
to previous evidence of the BMP-2 and BMP-4 acting as
stimulators on the chondrocytic maturation and anabolic
cells activity during matrix production14. Moreover,
rhBMP-2 induces expression of the cartilage and bone
markers in vitro, as well as formation of cartilage and bone
at ectopic and skeletal sites in vivo15-18. Shu et al. showed
that BMP-2 is crucial for chondrocyte proliferation and
maturation during endochondral ossification at the growth
plate sites of the BMP-2 knock out mices14. Our result of
the BMP-2 and BMP-4 decreased expressions at day 21st
could be explained by the fact that cartilage undergoes re-
sorption, and chondrocytes apoptosis in later stages of
chondrogenesis. Even not statistically significant, BMP-7
also showed decreased expression at 21st day. This could be
related to previous evidence of the BMP-7 gene and protein
expression being dramatically reduced in aged and degen-
erated cartilage. When synovial derived mesenchimal
steem cels in culture are exposed to high dose of BMP-7,
chondrogenesis is enhanced19. So, BMP-7 plays crucial role
in regulation of overall cartilage homeostasis20.
Regardless to early or late stages of the osteogenesis,
inhibitors were similarly expressed in osteocytes. In con-
trast, their expression in chondrocytes was different. Nog-
gin and follistatin were highly expressed in chondrocytes
of the 14th day of the experiment and their expression de-
creased at the 21st day. Inverse to noggin and follistatin,
was the expression of the gremlin and chordin - the lowest
at the 14th day and the highest at the 21st day of the exper-
iment.
Similarly to our model of ectopic ossteogenesis are
those of Nakamura et al., who have induced new bone for-
mation by exogenously administrated BMP-2, resulting in
noggin up regulation21. During early stages of the
chondrogenesis, noggin expression was localized in non -
hypertrophic chondrocytes, which coincides to expres-
sions of the BMP-2 and BMP-4. It is possible that these
BMPs stimulate noggin production in the chondrocytes,
as a part of autocrine regulation during osteogenesis.
Such opinion is further confirmed by Kwong et al., in
model of the long bone fracture healing4. These authors
have further developed theory of the influence of the ratio
of the inhibitors and BMPs, on the bone fracture repair, by
stating that exogenous osteoinduction or noggin blockade,
can improve endochondral ossification. After being ex-
posed to BMP-2, BMP-4 and BMP-6, noggin upregulation
could be explained as part of protective mechanism against
excessive amount of BMPs22,23. We found that at the 21st
day, noggin was localized in hypetrophic chondrocytes and
octeocytes. Compared to 14th day noggin expression is
lower, as well as expression of the BMP-2 and BMP-4 at
21st day in chondrocytes. As new bone trabecuae form,
noggin, similarly to BMPs shows the highest expression
localized in woven bone. Such relation of the BMPs and
noggin was previously described21.
In chondrocytes, noggin and chordin are upregulated
by inductors of chondrogenesis such as Indian hedgehog24.
Noggin blocks the effect of of BMPs by blocking alkaline
phoshatase synthesis as well as collagen and non-col-
lagenous proteins synthesis in osteoblast23. Noggin also
inhibits intramembranous ossification and prevents chon-
drogenesis during limbs development25-27. Transgenic mice
with noggin overexpression have decreased trabecular
bone volume and impaired osteoblastic function which
leads to severe osteopenia and fractures28. Lories showed
that noggin haploinsufficiency provides certain protection
to articular cartilage, against destruction in model of the
induced arthritis, while noggin overexpression caused car-
tilage more vulnerable in the models of the inflammation
driven cartilage destruction, systemic autoimmune arthri-
tis and joint ankylosis29. Null mutation of the noggin gene
leads to severe hyperplasia of the cartilage and multiple
joint fusions and leads to animal death. Haploinsufficien-
cy of the noggin causes carpal and tarsal fusions which re-
semble to some phenotypes of noggin haploinsufficienty in
humans30.
Abe et al. revealed that rh-noggin inhibits osteoblast
and osteclast formation in mice bone marow cell culture
and this effect could be prevented by addind exogenous
BMP-231. Our findings are in consistence with the major-
ity of cited authors and could additionally support the hy-
pothesis of negative feed back mechanism between
BMP-2, BMP-4 and noggin.
Regarding follistatin, we showed the same expression
pattern as noggin characterized by its upregulation in
early chondrogenesis and osteogenesis.
Tardif et al. found positive expression of follistatin,
gremlin and chordin (but not noggin) in articular cartilage
and synovial tissue. Expression of the follistatin and grem-
lin is upregulated in OA chondrocytes, but not in synovial
fibroblasts1. In humans and in OA dogs Tardif speculated
that follistatin regulation is mediated by proinflammatory
factors such as IFN-ã and TNF-á, while gremlin expression
is mediated by BMP-2 and -42. Therefore, follisattin may
have stronger link with the inflammatory processes in the
joint. Tardif also analyzed chordin expression and found
that it is also upregulated in OA chondrocytes but it is not
clear which factors regulate its expression3.
Zhang et al. suggest important roles of the chordin
during skeletal growth and endochondral ossification, being
inversely related to the chondrocyte maturation32. This is
consistent with our finding of chordin high expression in
chondrocytes at 21st day. Chordin is probably involved in
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inhibiting further chondrogenesis, since bone formation
begins.
Kwong et al. found that blockade of the chordin activ-
ity increases the rate of the osteogenic differentiation of
the human mesenchymal stem cells6. Kwong revealed the
most intense noggin and chordin expression in non - hy-
pertrophic and hypertrophyc chondrocytes, during frac-
ture healing, while BMP-2 expression was found in non -
hypertropic chondrocytes4. Also, noggin and chordin ex-
pression was detected in osteoblasts.
Wordinger et al. reported that gremlin regulates cell
proliferation and stem cell differentiation33. Also, gremlin
acts directly on endothelial cells to modulate angiogenesis
and endothelial cell migration. Canalis showed that grem-
lin null mices have decreased weight and body size, due to
shortened femoral length, a deformation found in young
mices, which has diminished in adult animals. It was con-
cluded that gremlin is not only neccesary for skeletal de-
velopment but also for postnatal skeletal homeostasis34.
BMP expression in fibrous membrane is the strongest
at day 21st, which corresponds to beginning of the bone
formation. BMP inhibitors showed constant level of ex-
pression throughout the experiment, except for gremlin,
which was somewhat less expressed at 21st day and 30th
day of the experiment. These patterns of expression of
osteoinductive proteins and their inhibitors indicate to fi-
brous membrane as a auto regulator of histogenetic pro-
cesses in the implant. Specifically, blood vessels of the con-
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Fig. 4. Expression levels of the BMPs and their inhibitors in chondrocytes during the early phase of the osteogenesis (14th day) and late
phase of the osteogenesis (21st day) in the osteocytes. * - statistically significant difference in relation to chondrocytes at day 14th and
osteocytes at day 21st. # - statistically significant difference in relation to chondrocytes at day 14th and 21st.
Fig. 5. Expression levels of the BMPs and their inhibitors in fibrocytes at 5th, 7th, 14th, 21st and 30th day of the experiment.
nective membrane form unique bridge between the
implant and the host. Via blood vessels BMPs and their in-
hibitors influence the events in the implant. Also connec-
tive membrane protects the surrounding tissue or the
whole host organism out of the extensive ectopic ossifica-
tion.
The results of our study have shown that level of the
BMP-2 and BMP-4 expression in chondrocytes is similar
to noggin and follistatin. All these factors have increased
levels of the expression at day 14th of the ectopic osteo-
genesis, which suggests their important roles in early
phases of the chondrogenesis. At day 21st we have detected
increased levels of gremlin and chordin expression in
chondrocytes, which suggests their important role in reg-
ulation of the osteogenesis. BMP-2, BMP-4 and BMP-7, as
well as all given inhibitors have the highest levels of the
expression at 21st day in the osteocytes, which suggests
their strong interactions in osteogenesis.
Conclusevly, specific interaction between BMPs and
their inhibitors during different stages of the chondro-
genesis and in osteogenesis is crucial for the process of
ectopic bone formation.
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IZRA@AJ BMP -2, -4 I -7 I NJIHOVIH ANTAGONISTA GREMLIN, HORDIN, NOGIN I FOLISTATIN
TIJEKOM EKTOPI^NE OSTEOGENEZE
S A @ E T A K
Mre`a osteoinduktivnih BMP molekula i njihovih ekstracelularnih antagonista sudjeluje u odr`avanju homeostaze
ko{tanog tkiva. Pri normalnoj osteogenezi va`ne su interakcije izme|u BMP-2, -4 i -7 molekula i njihovih inhibitora:
gremlin, folistatin, hordin i nogin. Obrazac ekspresije navedenih ~imbenika utvrdili smo na eksperimentalnom modelu
inducirane ektopi~ne ostogeneze u {takora. Rezultati su pokazali da je obrazac ekspresije BMP-2 i BMP-4 u hondro-
citima sli~an ekspresiji nogina i folistatina. Ekspresija ovih proteina pove}ana je 14. dana osteogeneze {to ide u prilog
njihove va`nosti u ranoj fazi hondrogeneze. Gremlin i hordin ja~e su izra`eni u kasnijoj fazi hondrogenze {to pokazuje
njihovu va`nu ulogu u inicijaciji osteogeneze. Izra`aj BMP molekula i njihovih inhibitora je na najve}oj razini 21. dana
u osteocitima iz ~ega se mo`e zaklju~iti njihova zna~ajna uloga u regulaciji osteogeneze.
L. \udari} et al.: Osteogenic BMPs and Inhibitors, Coll. Antropol. 37 (2013) 4: 1291–1298
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